• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫检查点受体的 IgV 结构域的 CC' 环在受体配体亲和力调节中起着关键作用。

The CC' loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation.

机构信息

Division of Biological Sciences, Poornaprajna Institute of Scientific Research, #4, 16th Cross, Sadashivnagar, Bangalore, 560080, India.

Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.

出版信息

Sci Rep. 2019 Dec 16;9(1):19191. doi: 10.1038/s41598-019-54623-y.

DOI:10.1038/s41598-019-54623-y
PMID:31844079
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6914781/
Abstract

Antibodies targeting negative regulators of immune checkpoints have shown unprecedented and durable response against variety of malignancies. While the concept of blocking the negative regulators of the immune checkpoints using mAbs appears to be an outstanding approach, their limited effect and several drawbacks, calls for the rational design of next generation of therapeutics. Soluble isoforms of the negative regulators of immune checkpoint pathways are expressed naturally and regulate immune responses. This suggests, affinity-modified versions of these self-molecules could be effective lead molecules for immunotherapy. To obtain better insights on the hotspot regions for modification, we have analysed structures of 18 immune receptor:ligand complexes containing the IgV domain. Interestingly, this analysis reveals that the CC' loop of IgV domain, a loop which is distinct from CDRs of antibodies, plays a pivotal role in affinity modulation, which was previously not highlighted. It is noteworthy that a ~5-residue long CC' loop in a ~120 residue protein makes significant number of hydrophobic and polar interactions with its cognate ligand. The post-interaction movement of CC' loop to accommodate the incoming ligands, seems to provide additional affinity to the interactions. In silico replacement of the CC' loop of TIGIT with that of Nectin-2 and PVR followed by protein docking trials suggests a key role of the CC' loop in affinity modulation in the TIGIT/Nectin pathway. The CC' loop appears to be a hotspot for the affinity modification without affecting the specificity to their cognate receptors.

摘要

针对免疫检查点负调节剂的抗体针对多种恶性肿瘤表现出前所未有的持久反应。虽然使用单克隆抗体阻断免疫检查点负调节剂的概念似乎是一种出色的方法,但它们的有限效果和几个缺点要求合理设计下一代治疗药物。免疫检查点途径负调节剂的可溶性同种型自然表达并调节免疫反应。这表明,这些自身分子的亲和力修饰版本可能是免疫治疗的有效先导分子。为了更好地了解修饰的热点区域,我们分析了包含 IgV 结构域的 18 种免疫受体:配体复合物的结构。有趣的是,这项分析表明,IgV 结构域的 CC'环,即与抗体的 CDR 不同的环,在亲和力调节中起着关键作用,而这一点以前并未得到强调。值得注意的是,在一个约 120 个残基的蛋白质中,一个约 5 个残基长的 CC'环与它的同源配体形成大量的疏水和极性相互作用。CC'环在与配体相互作用后的移动,似乎为相互作用提供了额外的亲和力。用神经钙黏蛋白-2 和 PVR 的 CC'环替换 TIGIT 的 CC'环,然后进行蛋白对接试验,提示 CC'环在 TIGIT/神经钙黏蛋白途径中的亲和力调节中起关键作用。CC'环似乎是亲和力修饰的热点,而不会影响其对同源受体的特异性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/c8c8254bba5b/41598_2019_54623_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/b1bdd2f1ca6f/41598_2019_54623_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/e0adfe4c8862/41598_2019_54623_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/1330af70f45e/41598_2019_54623_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/4287676afa85/41598_2019_54623_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/c8c8254bba5b/41598_2019_54623_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/b1bdd2f1ca6f/41598_2019_54623_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/e0adfe4c8862/41598_2019_54623_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/1330af70f45e/41598_2019_54623_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/4287676afa85/41598_2019_54623_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f38d/6914781/c8c8254bba5b/41598_2019_54623_Fig5_HTML.jpg

相似文献

1
The CC' loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation.免疫检查点受体的 IgV 结构域的 CC' 环在受体配体亲和力调节中起着关键作用。
Sci Rep. 2019 Dec 16;9(1):19191. doi: 10.1038/s41598-019-54623-y.
2
Pembrolizumab Induces an Unexpected Conformational Change in the CC'-loop of PD-1.帕博利珠单抗诱导程序性死亡受体-1(PD-1)CC'环发生意外的构象变化。
Cancers (Basel). 2020 Dec 22;13(1):5. doi: 10.3390/cancers13010005.
3
Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.免疫受体 PVRIG 识别和选择性识别配体 Nectin-2 的结构基础。
Structure. 2024 Jul 11;32(7):918-929.e4. doi: 10.1016/j.str.2024.03.012. Epub 2024 Apr 15.
4
Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).自然杀伤细胞受体T细胞免疫球蛋白和ITIM结构域(TIGIT)对nectin-2的识别。
J Biol Chem. 2017 Jul 7;292(27):11413-11422. doi: 10.1074/jbc.M117.786483. Epub 2017 May 17.
5
Sequence variety in the CC' loop of Siglec-8/9/3 determines the recognitions to sulfated oligosaccharides.Siglec-8/9/3的CC'环中的序列多样性决定了对硫酸化寡糖的识别。
Comput Struct Biotechnol J. 2023 Aug 21;21:4159-4171. doi: 10.1016/j.csbj.2023.08.014. eCollection 2023.
6
Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT.计算机辅助设计增强与 TIGIT 结合亲和力的 PVR 突变体。
Cell Commun Signal. 2021 Feb 8;19(1):12. doi: 10.1186/s12964-020-00701-y.
7
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.PVR/PVRL2与TIGIT/DNAM-1的相互作用作为癌症中一种新型免疫检查点轴和治疗靶点
Mamm Genome. 2018 Dec;29(11-12):694-702. doi: 10.1007/s00335-018-9770-7. Epub 2018 Aug 21.
8
The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.Nectin 家族配体 PVRL2 和 PVR 在癌症免疫和免疫治疗中的作用。
Front Immunol. 2024 Aug 2;15:1441730. doi: 10.3389/fimmu.2024.1441730. eCollection 2024.
9
Structural, mutational and biophysical studies reveal a canonical mode of molecular recognition between immune receptor TIGIT and nectin-2.结构、突变和生物物理研究揭示了免疫受体TIGIT与nectin-2之间分子识别的一种典型模式。
Mol Immunol. 2017 Jan;81:151-159. doi: 10.1016/j.molimm.2016.12.003. Epub 2016 Dec 12.
10
TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.TIGIT和CD96:癌症免疫治疗的新型检查点受体靶点
Immunol Rev. 2017 Mar;276(1):112-120. doi: 10.1111/imr.12518.

引用本文的文献

1
Gingipain regulates isoform switches of PD-L1 in macrophages infected with Porphyromonas gingivalis.牙龈蛋白酶调节牙龈卟啉单胞菌感染的巨噬细胞中PD-L1的异构体转换。
Sci Rep. 2025 Mar 26;15(1):10462. doi: 10.1038/s41598-025-94954-7.
2
Tim-3 pathway dysregulation and targeting in sepsis-induced immunosuppression.Tim-3通路失调与脓毒症诱导的免疫抑制中的靶向治疗
Eur J Med Res. 2024 Dec 18;29(1):583. doi: 10.1186/s40001-024-02203-w.
3
VSTM2A reverses immunosuppression in colorectal cancer by antagonizing the PD-L1/PD-1 interaction.

本文引用的文献

1
Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.人源激活免疫受体 DNAM-1 识别神经钙黏蛋白样蛋白-5 的结构基础。
J Biol Chem. 2019 Aug 16;294(33):12534-12546. doi: 10.1074/jbc.RA119.009261. Epub 2019 Jun 28.
2
Structural Basis of CD160:HVEM Recognition.CD160:HVEM 识别的结构基础。
Structure. 2019 Aug 6;27(8):1286-1295.e4. doi: 10.1016/j.str.2019.05.010. Epub 2019 Jun 20.
3
Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity.计算设计 PD-1 界面以提高 PD-L1 配体选择性。
VSTM2A 通过拮抗 PD-L1/PD-1 相互作用逆转结直肠癌的免疫抑制。
Mol Ther. 2024 Nov 6;32(11):4045-4057. doi: 10.1016/j.ymthe.2024.09.023. Epub 2024 Sep 17.
4
An in silico investigation on the binding site preference of PD-1 and PD-L1 for designing antibodies for targeted cancer therapy.基于计算机的 PD-1 和 PD-L1 结合位点偏好性研究及其在设计靶向癌症治疗抗体中的应用
PLoS One. 2024 Jul 25;19(7):e0304270. doi: 10.1371/journal.pone.0304270. eCollection 2024.
5
Clustering molecular dynamics conformations of the CC'-loop of the PD-1 immuno-checkpoint receptor.对程序性死亡蛋白1(PD-1)免疫检查点受体CC'环的分子动力学构象进行聚类分析。
Comput Struct Biotechnol J. 2023 Jul 13;21:3920-3932. doi: 10.1016/j.csbj.2023.07.004. eCollection 2023.
6
Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells.血小板衍生的 TLT-1 通过抑制 CD8+T 细胞促进肿瘤进展。
J Exp Med. 2023 Jan 2;220(1). doi: 10.1084/jem.20212218. Epub 2022 Oct 28.
7
Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1.分子动力学确定了与天然配体PD-L1结合的PD-1检查点受体中的半刚性结构域。
Front Bioeng Biotechnol. 2022 Oct 6;10:838129. doi: 10.3389/fbioe.2022.838129. eCollection 2022.
8
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.针对 LAG3/GAL-3 克服多发性骨髓瘤中的免疫抑制并增强抗肿瘤免疫反应。
Leukemia. 2022 Jan;36(1):138-154. doi: 10.1038/s41375-021-01301-6. Epub 2021 Jul 21.
9
Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage.替雷利珠单抗独特地结合 PD-1 的 CC' 环,具有缓慢解离速率和完全的 PD-L1 阻断作用。
FEBS Open Bio. 2021 Mar;11(3):782-792. doi: 10.1002/2211-5463.13102. Epub 2021 Feb 16.
10
Structural Insights into N-terminal IgV Domain of BTNL2, a T Cell Inhibitory Molecule, Suggests a Non-canonical Binding Interface for Its Putative Receptors.BTNL2 是一种 T 细胞抑制分子,其 N 端 IgV 结构域的结构见解表明其假定受体具有非典型结合界面。
J Mol Biol. 2020 Nov 6;432(22):5938-5950. doi: 10.1016/j.jmb.2020.09.013. Epub 2020 Oct 5.
Structure. 2019 May 7;27(5):829-836.e3. doi: 10.1016/j.str.2019.03.006. Epub 2019 Mar 28.
4
Structural Basis for CD96 Immune Receptor Recognition of Nectin-like Protein-5, CD155.CD96 免疫受体识别神经钙黏蛋白样蛋白-5、CD155 的结构基础
Structure. 2019 Feb 5;27(2):219-228.e3. doi: 10.1016/j.str.2018.10.023. Epub 2018 Dec 6.
5
Mechanisms of resistance to immune checkpoint inhibitors.免疫检查点抑制剂耐药的机制。
Br J Cancer. 2018 Jan;118(1):9-16. doi: 10.1038/bjc.2017.434. Epub 2018 Jan 2.
6
Molecular basis of human CD22 function and therapeutic targeting.人类CD22功能及治疗靶点的分子基础
Nat Commun. 2017 Oct 2;8(1):764. doi: 10.1038/s41467-017-00836-6.
7
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.不同的细胞机制是抗CTLA-4和抗PD-1检查点阻断的基础。
Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10.
8
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors.靶向信号淋巴细胞激活分子(SLAM)受体家族的新型抗骨髓瘤免疫疗法。
Oncoimmunology. 2017 Mar 28;6(5):e1308618. doi: 10.1080/2162402X.2017.1308618. eCollection 2017.
9
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.肿瘤中 PD-L2 的表达:与癌症抗 PD-1 治疗的相关性。
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761.
10
Recognition of nectin-2 by the natural killer cell receptor T cell immunoglobulin and ITIM domain (TIGIT).自然杀伤细胞受体T细胞免疫球蛋白和ITIM结构域(TIGIT)对nectin-2的识别。
J Biol Chem. 2017 Jul 7;292(27):11413-11422. doi: 10.1074/jbc.M117.786483. Epub 2017 May 17.